LL-37

LL-37 is a peptide derived from the human cathelicidin antimicrobial peptide, playing a role in innate immune defense and barrier function. It has been studied in relation to skin, respiratory, and mucosal immunity.

In experimental and niche clinical discussions, LL-37 is sometimes mentioned in connection with wound care or immune modulation, but its use is not broadly standardized across regions.

LL-37 participates in innate immune responses through several high-level mechanisms, including:

• Direct antimicrobial activity in vitro against certain bacteria and other pathogens
• Modulation of inflammatory signaling and chemotaxis
• Support of barrier integrity in epithelial tissues

How these mechanisms can or should be leveraged therapeutically is still the subject of ongoing research.

LL-37 itself is not a widely approved therapeutic product in most jurisdictions. Instead, it tends to appear in research settings or in limited experimental applications.

Any consideration of LL-37-related interventions should emphasize that they are typically outside conventional standards of care and may carry uncertainties in dosing, formulation, and long-term impact.

Potential concerns include local irritation or inflammatory responses and context-specific immune effects. Because LL-37 is active in immune regulation, unintended modulation of inflammation is a theoretical risk.

Robust safety characterization will require more controlled human data.

LL-37 is highly cytotoxic at high concentrations. Systemic administration is risky.

Use is typically restricted to topical applications in wound care research.

LL-37 may be investigated or cataloged as a standalone peptide or as part of experimental regimens that combine it with other agents aimed at barrier or immune function.

The formulation question that has actually been answered is concentration. Both published human trials used a topical preparation applied to a wound bed at 0.5, 1.6, or 3.2 mg/mL, and in the first-in-man study the highest strength performed no better than placebo while the lowest performed best (PMID 25041740). For a peptide with a documented cytotoxic ceiling, formulation strength is not a secondary detail.

Research on LL-37 includes in vitro and animal work on antimicrobial activity, wound healing, and immune modulation, as well as limited human data in specific conditions.

Translating these findings into routine clinical practice requires more evidence regarding efficacy, optimal context, and safety.

For deeper dives on this peptide, see:

• LL-37 benefits and areas of interest
• LL-37 side effects and safety context
• LL-37 dosing concepts (educational)
• LL-37 research and evidence overview

Has LL-37 been given to humans? Yes — topically, on chronic venous leg ulcers. A 34-patient first-in-man trial applied it twice weekly at 0.5, 1.6, or 3.2 mg/mL (PMID 25041740), and a 148-patient phase IIb followed with the two lower strengths (PMID 34687253). No published trial has injected LL-37 into a person.

Did those trials work? The small one did, at the low end: the 0.5 mg/mL group healed roughly six times faster than placebo (p=0.003) with mean ulcer area down 68%. The 3.2 mg/mL group was no different from placebo. The larger phase IIb then missed — no significant healing benefit over placebo across the full population, with a positive signal only in a post hoc subgroup of wounds at least 10 cm².

Why did the highest dose work worst? LL-37 is non-cell-selective. It kills E. coli at around 5 µM but is cytotoxic to human cells at 13–25 µM (PMID 9452503), acting on membranes by a detergent-like "carpet" mechanism (PMID 10417311). More peptide crosses from helping into harming.

If my body makes LL-37, is adding more safe? The disease literature argues otherwise. Elevated, abnormally processed cathelicidin drives rosacea inflammation — injecting those peptides into mouse skin caused it, and deleting the gene prevented it (PMID 17676051) — and in psoriasis LL-37 binds self-DNA to trigger interferon production by plasmacytoid dendritic cells, breaking tolerance to one's own DNA (PMID 17873860).

Is LL-37 approved anywhere? No. It has no approved indication in any major jurisdiction, and material sold as LL-37 has no labeled concentration, purity, or sterility standard behind it.